Quality Improvement Project to Evaluate Discharge Prescriptions in Children With Cystic Fibrosis
NAGIOS: RODERIC FUNCIONANDO

Quality Improvement Project to Evaluate Discharge Prescriptions in Children With Cystic Fibrosis

DSpace Repository

Quality Improvement Project to Evaluate Discharge Prescriptions in Children With Cystic Fibrosis

Show simple item record

dc.contributor.author Merino Sanjuán, Matilde
dc.contributor.author Chorro Marí, Verónica
dc.contributor.author Nwokoro, Chinedu
dc.contributor.author Christiansen, Nanna
dc.contributor.author Pao, Caroline
dc.contributor.author Gómez-Pastrana Durán, David
dc.contributor.author Climente Martí, Mónica
dc.date.accessioned 2019-11-15T15:14:01Z
dc.date.available 2019-11-15T15:14:01Z
dc.date.issued 2019
dc.identifier.uri https://hdl.handle.net/10550/72216
dc.description.abstract Introduction: Cystic Fibrosis (CF) requires multiple pharmaceutical treatments, elevating the risk of medication errors (ME), which may compromise patient safety. This study aimed to improve the quality of discharge prescriptions (DPs) using indicators following admissions for IV antibiotics in pediatric CF patients. Methods: This project involved a longitudinal observational retrospective descriptive study followed by a longitudinal quasi-experimental prospective phase between January 2013 and December 2016 in CF patients admitted to a London Children's Hospital. The CF pharmacist reviewed DPs. Six rights of medication administration were defined (6R): dose, drug, frequency, duration of treatment, pharmaceutical form, and route of administration. We classified ME according to 6R, including subtype of error: committed/omitted. We calculated quality indicators by dividing the number of each correct parameter defined by 6R by number of DPs. Retrospective results were used prospectively to describe and implement improvement strategies and safety actions. Results: The retrospective study phase included 42 CF children (100 hospital admissions and 1,343 drugs). The prospective phase included thirty-five children (55 admissions and 822 drugs). The total number of ME identified was 148 (78 committed; 70 omitted) in retrospective phase and 135 (19 committed; 116 omitted) in prospective phase. Quality indicators for drug and dose showed significant improvement after implementing safety strategies. The global quality indicator increased from 22% (retrospective) to 41.82% (prospective), but we did not achieve the previously defined quality standard value (50%). Conclusions: A retrospective review of DP by a CF Pharmacist identified failures in DP quality. Implementing improvement strategies improved prescribing. Integrating pharmacist within multidisciplinary team improves DP reducing errors.
dc.language.iso eng
dc.relation.ispartof Pediatric Quality & Safety, 2019, vol. 4, num. 5, p. e208
dc.rights.uri info:eu-repo/semantics/openAccess
dc.source Merino Sanjuán, Matilde Chorro Marí, Verónica Nwokoro, Chinedu Christiansen, Nanna Pao, Caroline Gómez-Pastrana Durán, David Climente Martí, Mónica 2019 Quality Improvement Project to Evaluate Discharge Prescriptions in Children With Cystic Fibrosis Pediatric Quality & Safety 4 5 e208
dc.subject Tecnologia farmacèutica
dc.subject Farmacèutic i pacient
dc.title Quality Improvement Project to Evaluate Discharge Prescriptions in Children With Cystic Fibrosis
dc.type info:eu-repo/semantics/article
dc.date.updated 2019-11-15T15:14:01Z
dc.identifier.doi https://doi.org/10.1097/pq9.0000000000000208
dc.identifier.idgrec 135143

View       (628.4Kb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics